Carl read the papersWhat it actually is
PNC-27 is a lab-built chimera: residues 12 to 26 of the p53 protein (the stretch that grabs a protein called HDM-2) joined to penetratin, a sequence that helps peptides cross cell membranes. 32 amino acids in total. It came out of a research group in Brooklyn, New York, first published in 2001.
The idea: many cancer cells carry HDM-2 on their outer membrane, while normal cells mostly do not. PNC-27 binds that membrane HDM-2 and forms pores, and the cell bursts. In culture it kills a long list of cancer cell types and leaves the normal cells tested alongside them alone.
How it’s thought to work
- Targets membrane HDM-2 — Binds HDM-2 sitting in cancer cell membranes, which normal cells mostly lack.
- Pore formation — Peptide and HDM-2 pair up and line pores in the membrane; electron microscopy shows the rings.
- Necrosis, not apoptosis — Cells burst rather than switching on programmed cell death. The group traced this to the penetratin part, in work on its shorter sister peptide PNC-28.
- Does not need working p53 — Killed p53-null cancer cells as well as those with normal or mutant p53 in the original 2001 study.
What the research says
The lab story is solid by this shelf's standards: cancer cell lines, cells taken fresh from two ovarian cancer patients, and a mouse model of leukaemia. That mouse work came from an independent group at City of Hope, though a company supplied the peptide. The often-quoted pancreatic cancer result in mice used its shorter sister, PNC-28, not PNC-27. What is missing is everything after that. There is no registered human trial on ClinicalTrials.gov, no published human safety data and no known dose. At least one core paper declares that its authors are inventors on PNC-27 patents.
- p53 residues 12 to 26 fused to penetratin; binds HDM-2 in cancer cell membranes and forms pores.
- Kills many cancer cell types in culture while sparing the normal cells tested alongside them.
- Mouse work: leukaemia with PNC-27 (an independent City of Hope study), pancreatic cancer with the shorter PNC-28.
- Zero registered human trials. The FDA warned patients off it in 2017 after finding bacteria in a product sold online.
Reported protocols
These are the doses the peptide community actually reports running (Reddit & forums), alongside published research — logged for education, not as a recommendation to use.
| Parameter | Commonly reported range |
|---|---|
| Dose | None. No safe or effective dose of PNC-27 is known in people |
| Human trials | None registered on ClinicalTrials.gov |
| Use | Laboratory research only |
| If you have cancer | Nobody should try to treat cancer with PNC-27 or any research peptide. See an oncologist, and get a second oncologist's opinion if you want one |
Common use cases
| Goal | Community protocol notes |
|---|---|
| Research only | cell and animal studies of membrane HDM-2 as a cancer target |
Injection & handling
No injection guidance, on purpose. No safe or effective dose of PNC-27 is known in people, and products sold to patients have been found contaminated with bacteria or made in a home kitchen. If you or someone close to you has cancer, the next step is an oncologist, not a vial.
Stacks it appears in
- None — PNC-27 is not part of any protocol or stack. A 'cancer stack' that includes it is a red flag, not a plan.
Sources
- Kanovsky et al. 2001, PNAS: p53 mdm-2-binding peptides selectively cytotoxic to transformed cells
- Sarafraz-Yazdi et al. 2010, PNAS: PNC-27 kills cancer cells by binding HDM-2 in their membranes
- Sarafraz-Yazdi et al. 2022, Biomedicines: PNC-27, a chimeric p53-penetratin peptide, forms membrane pores
- Bowne et al. 2008, Ann Surg Oncol: Penetratin in PNC-28 causes necrosis rather than apoptosis
- Michl et al. 2006, Int J Cancer: PNC-28 blocks pancreatic cancer cell growth in vivo
- Wang et al. 2020, Leukemia (City of Hope): Targeting membrane HDM2 in AML
- Pincus et al. 2024, Biomedicines: Poptosis review
- Sarafraz-Yazdi et al. 2015, Ann Clin Lab Sci: PNC-27 on patient-derived ovarian cancer cells
- Pharmacy Times, 12 Jan 2017: FDA says avoid PNC-27
- US Attorney's Office N.D. Alabama: United States v. Bishop (PNC-27)
- ClinicalTrials.gov search: PNC-27
- SAHPRA: Peptide Products - Public Information (May 2026)
